HANGZHOU, China, March 20, 2025 /PRNewswire/ — ZEEKR Intelligent Technology Holding Limited ("Zeekr Group" or the "Company") (NYSE: ZK), the world’s leading premium new energy vehicle group, today announced that it filed its 2024 annual report on Form 20-F for the fiscal year ended December 31, 2024 with the Securities and Exchange Commission on March 20, 2025. The annual report can be accessed on the Company’s investor relations website at https://ir.zeekrgroup.com.

The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to ir@zeekrlife.com.

About Zeekr Group

Zeekr Group, headquartered in Zhejiang, China, is the world’s leading premium new energy vehicle group from Geely Holding Group. With two brands, Lynk & Co and Zeekr, Zeekr Group aims to create a fully integrated user ecosystem with innovation as a standard. Utilizing its state-of-the-art facilities and world-class expertise, Zeekr Group is developing its own software systems, e-powertrain and electric vehicle supply chain. Zeekr Group’s values are equality, diversity, and sustainability. Its ambition is to become a true global new energy mobility solution provider.

For more information, please visit https://ir.zeekrgroup.com.

Investor Relations Contact

In China:

ZEEKR Intelligent Technology Holding LimitedInvestor RelationsEmail: ir@zeekrlife.com

Piacente Financial CommunicationsTel: +86-10-6508-0677Email: Zeekr@thepiacentegroup.com

In the United States:

Piacente Financial CommunicationsBrandi PiacenteTel: +1-212-481-2050Email: Zeekr@thepiacentegroup.com

Media Contact

Email: Globalcomms@zeekrgroup.com

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Woolpert-RS&H JV Selected for $249M Shared Capacity, Architecture and Engineering Contract to Support USACE Japan

The five-year contract will support a wide variety of facility and infrastructure…

Waters New Bioseparations Tools Accelerate and Improve Development of RNA-based Vaccines and Therapies Using LC-MS Analysis

News Summary: Waters new LC-MS grade reagents, enzymes, and software simplify large molecule RNA…

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically…